Please login to the form below
Tecentriq
This page shows the latest Tecentriq news and features for those working in and with pharma, biotech and healthcare.
Roche and Cend Therapeutics to evaluate pancreatic cancer combination therapy
Roche’s Tecentriq is a cancer immunotherapy that has the potential to be used in combination with other immunotherapies, targeted medicines and various chemotherapies across a broad range of cancers. ... In June this year, Tecentriq was approved by the
Latest news
-
Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection
Subcutaneously administering Tecentriq reduced the time needed for treatment compared to standard IV infusion. ... The investigational subcutaneous formulation combines Tecentriq with Halozyme Therapeutics’ Enhanze drug delivery technology.
-
EC approves Roche’s Tecentriq for early-stage lung cancer
Tecentriq has now become the first cancer immunotherapy approved in Europe for the treatment of certain types of early-stage NSCLC. ... The safety data taken from the study were consistent with Tecentriq’s known safety profile, while no new safety
-
New drug available on NHS will benefit lung cancer patients
Following approval from the Medicines and Healthcare products Regulatory Agency (MHRA), Roche's atezolizumab (Tecentriq) can be used to treat non-small cell lung cancer (NSCLC).
-
Roche's lung cancer combination treatment improves long-term survival
survival (PFS) over Tecentriq alone after an average of 10.9 months follow-up. ... plus Tecentriq in early and metastatic disease in both lung and oesophageal cancers.
-
Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
Roche had to withdraw its US accelerated approval for its immuno-oncology drug Tecentriq (atezolizumab) in combination with chemotherapy earlier this year when a post-marketing study failed to show benefit.
More from news
Approximately 72 fully matching, plus 90 partially matching documents found.
Latest Intelligence
-
Immuno-oncology in 2019: the rapid evolution continues
2019. The only drug that has any realistic chance of challenging Keytruda in NSCLC is Roche’s Tecentriq. ... The Tecentriq chemo trial, IMpower132, is the most important head-to-head with Keytruda (in non-squamous NSCLC).
-
The handover: Pfizer reshapes itself for a new era
The therapy area is dominated by Merck’s Keytruda, BMS’ Opdivo and Roche’s Tecentriq, but Pfizer is hoping that combinations such as its own Inlyta and Bavencio can help it
-
Cancer immunotherapy: What's on the horizon?
It’s not all been plain sailing, with BMS’ Opdivo (nivolumab) and Roche’s Tecentriq not doing as well as hoped in frontline NSCLC, revealing there are differences between checkpoint inhibitors – ... The drugmaker thinks Avastin may enhance
-
Europe vs the US: New drug product approvals
Tecentriq (for the treatment of urothelial carcinoma, only approved in the US), and Venclexta (for the treatment of chronic lymphocytic leukaemia, approved in the EU and US).
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- ONS data reveals significant decrease in COVID-19 antibodies
- UK government’s ‘science superpower’ ambitions to fail without clear plan, Lords committee warns
- How the Royal Society’s EiR programme can help to drive UK innovation
- Bayer’s Nubeqa receives FDA approval to treat metastatic prostate cancer
- Environment: where does the pharmaceutical industry stand?
- Moderna’s Omicron booster receives MHRA approval
- Lack of evidence for AstraZeneca’s COVID-19 vaccine says UK Department of Health
- NHS England outlines measures to boost capacity ahead of substantial winter pressures
- New research shows drug candidate may effectively treat antibiotic-resistant bacteria
- Sanofi and NIHR enrol first patient in immunisation study for RSV in infants
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- FDA approves Incyte’s Pemazyre as first targeted drug for bile duct cancer
- WHO, UNICEF and UNAIDS launch global alliance to end AIDS in children by 2030
- Creating content to trigger behaviour change
- Strategic commitment
PMHub
Lucid Group Communications Limited
WE’RE ON A MISSION
To transform lives through communication that changes behaviour and improves health outcomes....
Latest intelligence
- Environment: where does the pharmaceutical industry stand?
- ...
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
